| P2093 | author name string | W Mück | |
| | J Kuhlmann | |
| P2860 | cites work | Torsades de pointes occurring in association with terfenadine use | Q28334377 |
| | Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 |
| | Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues | Q30582507 |
| | Drug-drug interactions of new active substances: mibefradil example | Q33763217 |
| | Patient-oriented strategies for the prevention of drug interactions | Q33836464 |
| | Clinical pharmacokinetics of cerivastatin | Q34025199 |
| | Iatrogenic illness on a general medical service at a university hospital | Q34287838 |
| | Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group | Q34313874 |
| | Clinical pharmacokinetics of mibefradil | Q34756311 |
| | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions | Q36851934 |
| | Potential Drug Interactions in an Ambulatory Geriatric Population | Q37071042 |
| | Drug interactions in the elderly. How multiple drug use increases risk exponentially | Q38726888 |
| | Drug interactions that matter. A critical reappraisal | Q39554942 |
| | Drug interaction studies during drug development: which, when, how? | Q40629057 |
| | Drug-related hospital admissions | Q40842331 |
| | Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor | Q41077310 |
| | An approach to the assessment of therapeutic drug interactions with fixed combination drug products | Q41149693 |
| | Systematic screening for pharmacokinetic interactions during drug development | Q41155440 |
| | Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. | Q41176129 |
| | In vitro approaches to predicting drug interactions in vivo. | Q41692688 |
| | Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase | Q42147615 |
| | Computer based prescribing | Q42907909 |
| | Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population | Q44331882 |
| | Drug-induced illness as a cause for admission to a community hospital | Q44963457 |
| | Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population | Q45275902 |
| | Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions | Q50143669 |
| | FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. | Q52205708 |
| | Drugs--remarkably nontoxic. | Q52891899 |
| | Drug-related hospital admissions: a review of Australian studies published 1988-1996. | Q53808419 |
| | Rhabdomyolysis due to interaction of simvastatin with mibefradil | Q56832784 |
| | Assessment of adverse reactions within a drug surveillance program | Q57946560 |
| | Surveillance of drug therapy in the hospital | Q67069608 |
| | Lack of pharmacokinetic interaction as an equivalence problem | Q67904898 |
| | Adverse drug interactions | Q70467062 |
| | Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin | Q71182682 |
| | Adverse reactions to prescribed drugs in the elderly: a multicentre investigation | Q71254949 |
| | [Pharmacodynamic interactions between drugs] | Q71488142 |
| | Acute admissions to a geriatric assessment unit | Q71607045 |
| | Are medication record cards useful? | Q72153058 |
| | Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility | Q72819069 |
| | Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use | Q73244405 |
| | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes | Q73846452 |
| | From the Food and Drug Administration | Q74157379 |
| | THE HAZARDS OF HOSPITALIZATION | Q76687654 |
| | The influence of information provided by patients on the accuracy of medication records | Q77074825 |
| | A fatal drug interaction between clozapine and fluoxetine | Q77211280 |
| | ["Clinically significant" new drug interactions] | Q77295563 |
| | Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions | Q77309922 |
| | In vitro metabolic interaction studies: experience of the Food and Drug Administration | Q78074910 |
| | DRUG TOXICITY IN MAN: THE PROBLEM AND THE CHALLENGE | Q78494967 |
| P433 | issue | 10 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 715-725 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Clinical-pharmacological strategies to assess drug interaction potential during drug development | |
| P478 | volume | 24 | |